Ubrelvy and Reyvow Will Be New Options to Treat Migraine

March 2020

Ubrelvy (yoo-BREL-vee, ubrogepant) and Reyvow (RAY-vow, lasmiditan) will be new oral meds to treat acute migraine in adults.

Ubrelvy is the first med in a new class called "gepants"...and Reyvow is the first med in a new class called "ditans."

But don't expect these meds to be on your formulary.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Practice Use "Housekeeping" Strategies in Med Rooms for Patient Safety
Look-Alike/Sound-Alike Stop Mix-Ups With Nizatidine and Tizanidine in Their Tracks
Med Safety Don't Be Afraid to Speak Up for Safety
Infectious Diseases Anticipate More Dalbavancin or Oritavancin Orders
Mental Health Have a Plan for Battling Burnout
Sickle Cell Disease Be Familiar With Adakveo and Oxbryta for Sickle Cell Disease
Infection Control Use Infection Control Measures in Light of Coronavirus
Cardiology Don't Be Surprised to See Some Heart Patients Get Colchicine
Migraine Ubrelvy and Reyvow Will Be New Options to Treat Migraine